Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c

Outlook Therapeutics (NASDAQ: OTLK) reported Q3 EPS of ($0.09). Revenue for the quarter came in at $9 thousand.

For earnings history and earnings-related data on Outlook Therapeutics (OTLK) click here.

You May Also Be Interested In

• OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
• NV Gold closes final tranche of private placement, raising $1.4M
• Goldcana closes C$2M private placement, issues 8M units